Showing 463 results
-
Media Release /
-
Media Release /
-
Media Release /- In a well-controlled, randomized, open-label study, Gilenya patients had higher treatment retention rates at one year, 81.3% vs. those on injectable DMTs, 29.2% - Throughout the study almost 10…
-
Media Release /Three leading US cardiology societies have jointly issued a clinical practice guideline update that has redefined standard of care treatment for heart failure and given Entresto® a strong Class I…
-
Media Release /-- Pivotal placebo-controlled study data show Exjade significantly decreases iron burden in NTDT patients versus placebo, with similar overall adverse event rate1-- Patients with NTDT accumulate…
-
Media Release /- Data show adult patients may achieve durable response rates, with 13 of 19 evaluable patients with relapsed/refractory non-Hodgkin lymphomas responding to therapy(1)- Recent milestones for Novartis…
-
Media Release /- Jadenu (deferasirox), a new formulation of Exjade (deferasirox), is the only once-daily oral tablet for iron chelation- Jadenu, taken with or without food, simplifies daily treatment administration…
-
Media Release /Afinitor led to an unprecedented median overall survival of 44 months, which represents a clinically meaningful while not statistically significant improvement(1)Pancreatic NET (pNET) affects about 2…
-
Media Release /US FDA has classified drug shortage status as resolved1Novartis capacity to produce Pluvicto will continue to grow with anticipated expansions to the manufacturing network in the US and globally…
-
Media Release /FDA approval based on robust Phase III data in which Cosentyx® (secukinumab) showed rapid relief from symptoms of hidradenitis suppurativa (HS) as early as Week 21 As the only IL-17A…
